Ubs Oconnor LLC Keros Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

$1.44 Billion
Q1 2025

A detailed history of Ubs Oconnor LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 115,518 shares of KROS stock, worth $1.69 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

115,518

Holding current value

$1.69 Million

% of portfolio

0.08%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$10.15 - $16.1 $655,903 - $1.04 Million	64,621 Added 126.96%	115,518 $1.18 Million
Q4 2024 Feb 14, 2025	BUY	$15.64 - $70.0 $408,907 - $1.83 Million	26,145 Added 105.63%	50,897 $805,000
Q3 2024 Nov 14, 2024	BUY	$41.68 - $58.07 $95,822 - $133,502	2,299 Added 10.24%	24,752 $1.44 Million
Q2 2024 Aug 14, 2024	BUY	$44.58 - $66.89 $240,732 - $361,206	5,400 Added 31.67%	22,453 $1.03 Million
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $121,345 - $207,281	2,941 Added 20.84%	17,053 $1.13 Million
Q4 2023 Feb 14, 2024	SELL	$27.12 - $41.05 $1.25 Million - $1.9 Million	-46,229 Reduced 76.61%	14,112 $561,000
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $157,850 - $215,100	5,000 Added 9.03%	60,341 $1.92 Million
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $2.06 Million - $2.82 Million	55,341 New	55,341 $2.22 Billion
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $6,879 - $9,847	166 Added 0.37%	45,484 $1.94 Million
Q4 2022 Feb 14, 2023	BUY	$39.45 - $51.77 $473,281 - $621,084	11,997 Added 36.0%	45,318 $0
Q3 2022 Nov 14, 2022	SELL	$27.8 - $40.12 $667,200 - $962,879	-24,000 Reduced 41.87%	33,321 $1.25 Billion
Q2 2022 Aug 12, 2022	BUY	$26.03 - $67.04 $841,315 - $2.17 Million	32,321 Added 129.28%	57,321 $1.58 Million
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $1.05 Million - $1.48 Million	25,000 New	25,000 $1.36 Million

Others Institutions Holding KROS

# of Institutions

178

Shares Held

36.4M

Call Options Held

938K

Put Options Held

1.39M

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $377M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account